Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Correction: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

The Original Article was published on 01 March 2011

Nat. Rev. Clin. Oncol. 8, 210–221 (2011); doi:10.1038/nrclinonc.2011.21

In the Review article published in the April issue of Nature Reviews Clinical Oncology there were errors in the clinical data presented in Tables 1 and 2. In addition, the primary end point of the adjuvant AVANT and NSABP-C-08 trials should have been disease-free survival (DFS) instead of progression-free survival (PFS). The errors have been corrected for the HTML and PDF versions of the article.

Authors

Additional information

The online version of the original article can be found at 10.1038/nrclinonc.2011.21

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ebos, J., Kerbel, R. Correction: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 316 (2011). https://doi.org/10.1038/nrclinonc.2011.74

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.74

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing